Clinical Trial: A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815665) titled 'A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma' on Aug. 31.

Brief Summary: A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: Metastatic Urothelial Carcinoma Metastatic Urothelial Carcinoma (UC)

Intervention: DRUG: Ivonescimab Dose 1

First ivonesci...